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Abstract
A variety of mutations in lentiviral vector expression systems have been shown to generate a non-
integrating phenotype. We studied a novel 12 base-pair U3-LTR integrase attachment site deletion 
(U3-LTR att site) mutant and found similar physical titers to the previously reported integrase 
catalytic core mutant IN/D116N. Both mutations led to a greater than two log reduction in vector 
integration; with IN/D116N providing lower illegitimate integration frequency, while the U3-LTR 
att site mutant provided a higher level of transgene expression. The improved expression of the 
U3-LTR att site mutant could not be explained solely based on an observed modest increase in 
integration frequency. In evaluating processing, we noted significant differences in unintegrated 
vector forms, with the U3-LTR att site mutant leading to a predominance of 1-LTR circles. The 
mutations also differed in the manner of illegitimate integration. The U3-LTR att site mutant 
vector demonstrated integrase-mediated integration at the intact U5-LTR att site and non-integrase 
mediated integration at the mutated U3-LTR att site. Finally, we combined a variety of mutations 
and modifications and assessed transgene expression and integration frequency to show that 
combining modifications can improve the potential clinical utility of non-integrating lentiviral 
vectors.
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INTRODUCTION
The ability to integrate stably within target cells has been a distinct advantage of retroviral 
and lentiviral vectors. However, these vectors have been associated with a risk of insertional 
mutagenesis (IM)1–3. To address this concern, non-integrating lentiviral vectors (NILV) have 
been developed for applications where integration is not required4–7. Such vectors would be 
most suitable for applications when transient expression of the transgene is desired8,9, 
transducing non-proliferating cells5,10–12, or as donor templates for use in zinc finger 
nuclease and transcription activator-like effector nuclease systems13–16.
HIV-1 primarily relies upon integrase (IN) to catalyze the integration of viral DNA into the 
target cell DNA. The reaction involves an episomal template along with three well-defined 
catalytic steps: 3’-end processing, DNA strand transfer, and a disintegration reaction. This 
process requires a complete reverse transcription reaction, an intact IN molecule and 
available U3 and U5 attachment sites for IN within the viral long terminal repeats 
(LTRs)17–19. HIV-1 infected cells are known to contain integrated provirus, unintegrated 
linear virus DNA as well as 1-LTR or 2-LTR circular forms. The 1- and 2-LTR circles arise 
through homologous recombination (HR) or non-homologous end-joining (NHEJ), 
respectively20–22. In this paper, insertions of vector DNA into a cell genome by non-
integrase mediated methods are referred to as illegitimate integrations.
IN mutations at the highly conserved amino acid positions D64, D116 and E152 disable the 
catalytic activity of IN by interfering with 3’-end processing, DNA strand transfer activities, 
and disintegration23. NILV generated using these mutant IN proteins are both infectious, 
express the vector transcript, and are associated with a marked reduction in vector 
integration4–6,10,24–27. A second approach is to induce aberrant reverse transcription by 
deletion of the 3’ polypurine tract (PPT) within the vector backbone11. A third, less well 
studied approach, is altering the LTR attachment (att) sites by mutagenesis of the CA 
dinucleotide recognition sequence within the U3 and U5 att sites; these mutations have been 
shown to inhibit integration while retaining infectivity at approximately 40% and 10% of 
wild-type virus, respectively18.
In the current study, a novel non-integrating vector with an ablation of the LTRs entire 12 
base-pair U3 att site was evaluated, as compared with IN catalytic core mutants, in order to 
inhibit integration while reducing the risk of reversion mutations. How different mutations 
alter the processing of vector transcripts, as well as their effect on NHEJ and HR, was also 
evaluated. Finally, the rate of illegitimate integration and vector expression was assessed for 
IN, LTR att, and PPT mutations alone or in combination.
RESULTS
Evaluation of integrase and LTR attachment site mutant non-integrating lentiviral vectors
Three novel non-integrating lentiviral vectors were generated: one with an 11 base-pair 
deletion within the U5 region of the 5’ LTR att site, a second with a 12 base-pair deletion 
within the U3 region of the 3’ LTR att site, and a third containing an extended mutation in 
the C-terminus of IN (Figs. 1A, B). The novel vectors were compared to previously reported 
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point mutations in IN23,24,28,29. While the mutations created were not predicted to 
significantly alter virion assembly24, this was tested experimentally by determining the 
physical titer (p24) of the vector. As shown in Figs. 1C and 1D, the level of p24 in vector 
supernatants from mutant vectors was similar to that measured from integration-competent 
vectors.
To determine if the mutants were infectious, lentiviral vectors containing eGFP were 
generated and used to transduce HEK293 cells. As shown in Figs. 2A and 2B, deletions 
within the C-terminus of IN and at the U5-LTR att site did not provide significant gene 
transfer while the IN mutants IN/D116N and IN/E152V and the novel U3-LTR att site 
deletion mutant demonstrated similar vector expression in HEK293 cells. Based upon this 
data, subsequent studies utilized these latter three constructs.
In proliferating cell cultures, the average vector copy per cell from non-integrating vectors 
decreases with time. Therefore, determining infectious titer by traditional titer methods is 
problematic. To assess whether physical titer (as measured by p24 ELISA) reflects 
infectious titer, the amount of vector was normalized using p24, then vector DNA was 
measured four hours after transduction. As shown in Fig. 2C, physical titer correlated with 
vector copy number. Based on this finding, p24 levels were used to normalize the amount of 
vector product in subsequent experiments.
Gene expression with non-integrating vectors
To evaluate transgene expression with non-integrating vectors, firefly luciferase expression 
was assessed in HEK293 cells. Interestingly, after 3 days the LTR/U3 vector demonstrated 
higher transgene expression than the IN mutants relative to integrase competent vector (Fig. 
3). Additionally, GFP expression was assessed in transduced HEK293 cells over a twenty-
one day period. As would be predicted for NILV in dividing cells, the percentage of GFP 
expressing cells and the vector DNA content declined overtime (Figs. 4A, B). LTR/U3del 
transduced cells maintained a level of gene transfer that was approximately 20% of 
integration-competent vector at 21 days, while expression from IN mutants was 
approximately 5% of integration-competent vector. Fluorescence at day 21 was not due to 
residual GFP protein alone; GFP mRNA was still detectable twenty-one days after 
transduction (Fig. 4C). Similar to the observations with luciferase, the LTR/U3del vector 
provided higher and more persistent GFP expression than the IN mutants (Fig. 4A) despite 
similar levels of vector DNA (Fig 4B).
Frequency of illegitimate integration with non-integrating vectors
The disparities observed with the varied levels of transgene expression suggested there may 
also be significant variation in the frequency of illegitimate integration by NILV. To 
determine the frequency of integration, a colony formation assay was performed using 
vectors containing an antibiotic resistance transgene and drug selection of transduced HEK 
293 cells. As shown in Fig. 5, the non-integrating vectors significantly reduced the 
frequency of illegitimate integration at least 2 logs below that of an integration-competent 
vector. LTR/U3del integrated at a significantly higher frequency than the integrase mutant 
IN/D116N, but the difference is smaller than predicted when considering the differences in 
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transgene expression (Figs. 3, 4A). Combining the IN and U3-LTR att site deletion 
mutations resulted in a significantly reduced frequency of integration as compared to either 
mutation independently.
Insertion-site analysis of non-integrating vectors
To further evaluate vector integration and expression, vector insertion sites were evaluated. 
The vector-genome junctions were amplified, sequenced and analyzed for the canonical 
features associated with integrase-mediated insertion as well as other means of integration, 
including NHEJ and/or HR. The results of this analysis are depicted in Fig. 6. As expected, 
the integration competent control vectors insertions demonstrated a 5 bp repeat of genomic 
DNA flanking the vector and end-processing of the integrase attachment sites as indicated 
by the presence of terminal CA dinucleotides. Integrase mutant vectors (IN/D116N) lack 
these findings and demonstrate insertions and/or deletions at the vector-genome junctions. 
Interestingly, LTR/U3del vectors demonstrate insertions and deletions at the 5’ LTR vector-
genome junction but display the canonical features associated with integrase-mediated 
insertion at the 3’ LTR. Combining the LTR deletion with the IN mutation was able to 
recapitulate the insertions or deletions observed with IN/D116N at both LTR junctions, 
indicative of non-integrase mediated insertions.
The distribution of circular vector DNA transcripts amongst cells transduced with 
integrase and LTR attachment site mutant vectors
To further evaluate NILV processing, the relative distribution of unintegrated vector was 
determined by Southern blot analysis of low molecular weight DNA (Fig. 7A). Three days 
after transduction, circular forms were the predominant episomal form for wild-type, IN 
mutant, and LTR att site mutant vectors (Fig. 7A). While 1-LTR circles were detected 
amongst all three populations of transduced cells, integrase mutants have equal or greater 
number of 2-LTR circles in comparison with 1-LTR circles. In support of this finding, 
quantitative PCR analysis found that IN mutant vectors have a four-fold increase in 2-LTR 
circles compared to the LTR/U3att vector (Fig. 7B).
To assess the relative amount of 1-LTR circles, standard PCR was utilized as quantitative 
PCR methods cannot distinguish 1-LTR circles and linear transcripts. Three days after 
transduction, 1-LTR circles could be detected in cells transduced with wild-type, IN mutant, 
and LTR att site mutant vectors (Fig. 7C). However, 1-LTR circles persisted during the 
twenty-one day observation period in cells transduced with wild-type and LTR/U3del 
vectors but not in the IN mutants.
The fate of episomal vector DNA in cells deficient for non-homologous end-joining 
process
As 2-LTR circle formation is reported to involve NHEJ, wild-type and DNA-PKcs-deficient 
MO59J human glioma cell lines were used to evaluate the distribution of unintegrated vector 
DNA. DNA-PKcs is a necessary component of several DNA damage repair pathways, 
including NHEJ30. As determined by Southern blot analysis and quantitative PCR, wild-type 
MO59K cells transduced with the LTR/U3del vector had less 2-LTR circles than wild-type 
and IN/D116N vectors (Figs. 8 A, B), with a relative distribution similar to that observed in 
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HEK293 cells (Figs. 7 A, B). In contrast, 2-LTR circles did not predominate in DNA-PKcs-
deficient cells regardless of vector type (Figs. 8 A, B). This suggested that 2-LTR circles in 
cells transduced with IN mutant vectors are formed, at least in part, by DNA-PKcs-
dependent NHEJ activities.
Optimizing NILV vectors for expression while minimizing illegitimate integration
In order to identify clinically useful NILV designs, the integration frequency of various 
combinations of NILV mutations were compared. As Kantor and colleagues have shown, 
there is decreased integration with a deletion in the 3’ PPT11. We evaluated pairing LTR/
U3att with the 3’ PPT deletion with and without IN/D116N. Similar to results reported by 
Kantor et al. and Tareen et al.7,11, pairing ΔPPT with IN/D116N provided a modest 
reduction in integration as compared to either mutation individually (Fig. 9), indicating that 
each modification works independently to inhibit integration. Combining the ΔPPT 
modification with LTR/U3att did not alter the frequency of integration compared to either 
modification alone. In contrast, combining the IN/D116N mutation with LTR/U3att did 
decrease integration suggesting the mutations work independently. Combining all three 
mutations (ΔPPT, IN/D116N and LTR/U3att) did not offer any additional improvement to 
integration frequency reduction.
NILV have also been associated with significantly reduced levels of transgene expression 
relative to integration competent vectors. The vectors studied here (ΔPPT, IN/D116N and 
combined ΔPPT/IN/D116N) show similar levels of expression (Fig. 10) consistent with 
previous reports5,11,27,31,32. Pairing the LTR/U3att and ΔPPT mutations did not affect 
expression. However, pairing the IN/D116N mutation with LTR/U3att modification resulted 
in a significant decrease in vector expression (Fig. 10).
We created a vector containing the ΔPPT, LTR/U3att, and IN/D116N mutations to 
investigate if transgene expression is affected. The triple mutant vector produced levels of 
transgene expression similar to those observed with all vectors containing the IN/D116N 
mutation. These findings suggest that the decreased illegitimate integration associated with 
IN/D116N is at the expense of expression.
DISCUSSION
The goal of this study was to evaluate a novel LTR att site mutation for transgene expression 
and illegitimate integration. The 12 base-pair deletion in this novel LTR/U3del vector is 
larger than the point mutants described by Nightingale et al.4 in order to decrease the 
chances of reversion mutations. Overall the LTR/U3del had higher and more persistent gene 
expression compared to IN mutations, but also was associated with a higher rate of 
illegitimate integration. Differences in processing appeared to contribute to the differences 
observed in vector expression and integration frequency. A novel mutant consisting of an 11 
base-pair deletion of the U5-LTR att site was also evaluated that generated vector particles 
but failed to provide significant expression in transduced cells. This mutation was likely 
unsuccessful due to defective reverse transcription (RT), attributed to overlap of the U5-LTR 
att site and the RT primer binding site necessary for first strand synthesis33,34,35.
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The novel LTR/U3att vector was compared to the previously published IN mutation IN/
D116N5,6,26,27. Vector integration frequency was similar to that reported by Yanez-Munoz et 
al. using a D64 IN mutant (reversion rate of 1 in 815)6 but there was a modest 2.7 fold 
increase in integrations with the LTR/U3att vector versus the IN/D116N. Interestingly, 
combining the LTR and IN mutations significantly reduced the frequency of integration as 
compared to either mutation independently, in contrast to previous studies combining IN and 
LTR att site point mutations4,10. The previous LTR/U3 att mutations were point mutation 
and it is possible the relatively large deletion used in our study provided for this difference 
by reducing the chance of any latent binding of integrase to the attachment site.
Insertion site analysis revealed non-integrase mediated insertion at the ablated U3 att site of 
the 3’LTR-genome junction (Fig. 6), similar to what has been observed with IN 
mutants4,36–38. However the intact U5 att site at the 5’LTR-genome junction displayed 
features associated with integrase mediated insertion, consistent with the ability of intact 
integrase to interact with each attachment site independently18. This difference in processing 
LTR/U3att mutants presumably contributes to the increased illegitimate integration 
observed.
Interestingly, the modest increase in illegitimate integration rates between the mutations 
were not consistent with the larger differences in vector expression (Figs. 4, 5). To 
investigate this further, we evaluated the processing of non-integrated vector DNA. Despite 
similar levels of vector DNA, more GFP-expressing cells were detected upon transduction 
with LTR/U3del than IN mutants. This observation was associated with differences in the 
ratio of 1-LTR and 2-LTR vector forms. At the point of maximal transgene expression, IN/
D116N and IN/E152V transduced cells contained nearly four-to-five times as many copies 
of 2-LTR circular vector DNA relative to LTR/U3del transduced cells (Fig. 7B). In contrast, 
1-LTR circles were the predominate form in cells transduced with LTR/U3del vector (Fig. 
7A). Given that LTR/U3del maintains higher transgene expression despite similar total 
vector DNA, further work is warranted to determine if 1-LTR circles facilitate higher and/or 
more persistent gene expression than 2-LTR circles. Possible mechanisms meriting further 
investigation include improved trafficking to the nucleus and resistance to degradation. The 
presence of a functional integrase protein allows for its binding to the wild-type U5-LTR att 
site for nuclear localization, while providing steric hindrance protecting the viral DNA ends 
from exonuclease activity39. The predominance of 1-LTR episomes can also improve vector 
viability. 2-LTR circles are derived from linear episomes as products of NHEJ of the viral 
DNAs 5’ and 3’ ends. Linear episomes are readily degraded by exonuclease activity which 
could lend to reduced transgene expression, whereas circular DNA is protected from 
exonuclease activity40.
Formation of 2-LTR circles is believed to be dependent upon NHEJ-double strand break 
DNA repair mechanisms, such as Ku-80, XRCC4, DNA ligase 4, and DNA-PKcs41. NILV 
transduction of DNA-PKcs-deficient cells suggests that a U3-LTR att site deletion may 
negatively influence NHEJ-mediated vector DNA circularization thereby limiting the 
number of 2-LTR circles (Fig. 8). Another explanation could be due to the proximity of the 
U3 LTR att site deletion which is immediately adjacent to the vectors 3’ PPT. The PPT acts 
as a primer site for second strand synthesis during RT and Kantor et al. have shown that 
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deletion of this element results in aberrant RT and the preferential production of 1-LTR 
circles11. Deletion of the juxtaposed U3 attachment site may also affect RT in a similar 
fashion. The results of this study suggest that IN and LTR att site mutations may 
differentially influence the circularization of unintegrated vector DNA.
It was observed that combining the IN and LTR mutations led to an improved reduction in 
integration frequency as compared to either mutation independently (Fig. 5). As NILV have 
been generated by deleting the 3’ PPT, we evaluated this mutation in combination with IN 
and LTR/U3att mutations. Combining ΔPPT with IN/D116N provided between a 2 and 3 
fold reduction in integration (Fig. 9), similar to previous observations when combined with a 
D64E IN mutation11. Interestingly, combining the ΔPPT and LTR/U3att mutation provided 
little or no reduction in integration frequency (Fig. 9). This suggests they evoke similar 
alterations in the processing of episomal DNA.
Combining ΔPPT and LTR/U3att had no effect on transgene expression as compared to 
either mutation alone, however, combining ΔPPT, LTR/U3att or both together with IN/
D116N resulted in a significant reduction in transgene expression (Fig. 9). The results show 
a trend of reduced transgene expression when the vector contains the IN mutation (Fig. 10). 
Hence, many of the vector combinations with the lowest frequencies of integration also 
demonstrated the lowest levels of transgene expression (Figs. 9, 10). Therefore, design of 
NILV for clinical applications should balance the risk of insertional mutagenesis and the 
level of vector expression. The risk of insertional mutagenesis with NILV is dependent on 
both vector integration rates and vector dose; if a vector with low integration rates requires 
significantly higher doses the safety benefit could favor a vector with higher expression.
This study suggests that the type of mutation used to generate non-integrating lentiviral 
vectors can influence cellular processing of vector transcripts. Such data will be important 
when attempting to design non-integrating vectors that maximize vector expression with low 
frequencies of integration and when considering transduction of target cells that may be 
defective in DNA repair pathways.
MATERIALS AND METHODS
Cell culture and reagents
HEK293 and HEK293T cells were purchased from American Type Culture Collection 
(Manassas, VA). MO59J and MO59K cell lines were kindly provided by D. Gilley (Indiana 
University School of Medicine, Indianapolis, IN). All cell lines were maintained in DMEM 
(Invitrogen, Carlsbad, CA), supplemented with 10% fetal bovine serum and 1% penicillin/
streptomycin at 37°C with 5% CO2.
Vector plasmids consisted of the eGFP expressing pcDNA-CS-CGW42 (kindly provided by 
P. Zoltick, Children’s Hospital of Philadelphia, Philadelphia, PA), the gag-pol expressing 
pMDL, the VSV-G envelope expressing pMDG, and the rev expressing pRSV-rev plasmid 
(all kindly provided by Cell Genesys, South San Francisco, CA)43.
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Construction of integrase and LTR attachment site mutant vector plasmids
For construction of the integrase deletion mutant IN/Δ174–288, digestion of the pMDL 
plasmid with AflII and subsequent base fill-in created an early stop codon within the 
integrase coding sequence. Two integrase missense mutants, IN/D116N and IN/E152V, were 
generated by site-directed mutagenesis of pMDL. Site-directed mutagenesis was performed 
using a Quik Change II XL Site-Directed Mutagenesis Kit (Stratagene, Cedar Creek, TX) 
according to the manufacturer’s specifications.
For generation of LTR/U3del, the 3’-LTR from the pcDNA-CS-CGW was subcloned into 
pZero2 (Invitrogen, Carlsbad, CA) at an upstream Asp718 and a downstream ApaI 
restriction sites. Site-directed mutagenesis was performed on the resulting plasmid, allowing 
for the deletion of the twelve base-pair integrase attachment site. For generation of LTR/
U5del, the 5’-LTR from pcDNA-CS-CGW was subcloned into pcDNA3 (Invitrogen, 
Carlsbad, CA) at an upstream SspI restriction site and a downstream NotI restriction site. 
Site-directed mutagenesis was performed deleting the eleven base-pair integrase attachment 
site. Incorporation of a bleomycin resistance transgene in lieu of eGFP was accomplished by 
insertion using unique AgeI and XhoI restriction enzyme sites. A deletion of the transfer 
plasmids 3’ polypurine tract (ΔPPT) was incorporated by standard restriction site insertion 
of the modified region synthesized by GeneArt (Life Technologies, Grand Island, NY). The 
mutations were confirmed by DNA sequencing.
Vector production and measurement of physical and infectious titer
VSV-G pseudotyped vector particles were produced by a four-plasmid calcium phosphate 
transient transfection method described previously44. All vector supernatants were treated 
with Benzonase (Novagen, San Diego, CA) to remove residual plasmid DNA, as previously 
described45. Triplicates of three dilutions (10−3, 10−4, and 10−5) of supernatant were 
analyzed for p24 gag capsid protein production using a p24 gag ELISA kit (Beckman 
Coulter, Fullerton, CA). The infectious titer of integration-competent vectors was 
determined in HEK293 cells by a method described previously44.
Transduction of cell lines and assessment of GFP or LUC expression
HEK293 cells, seeded at 105 cells per well of a six-well plate or 3 × 105 cells per T25 flask 
24 hours prior to transduction, were incubated with vector in the presence of 8 µg/ml of 
polybrene for 4 hours at 37°C. Transductions, performed in duplicate, utilized vector 
normalized for p24 (325 ng of p24 corresponding to an estimated MOI of five). GFP 
expression was assessed using a FACScan cytometer and CellQuest analysis software 
(Becton-Dickinson, San Jose, CA). For measurement of LUC expression, cell lysates were 
prepared from transduced cells, upon which 10 µg of protein per sample was added per well 
of a 96-well plate. LUC activity was measured as light intensity upon the addition of the 
LUC substrate, luciferin (Luciferase Assay System, Promega, Madison, WI).
MO59J and MO59K cells, seeded at 3 × 105 cells per 100 mm dish 24 hours prior to 
transduction and transduced with vector supernatant containing 2000 ng of p24.
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Measurement of integration frequency by antibiotic resistant colony forming assay
Vectors containing a bleomycin resistance transgene were generated for measurement of 
integration frequency as described above. HEK293 cells seeded at 105 cells per well, were 
transduced with vector supernatant normalized by p24 content with 10 replicates per vector. 
The selection reagent Zeocin™ (Life Technologies; Carlsbad, CA), at a concentration of 500 
µg/mL, was added to the media 48 hours post-transduction. The cells were incubated in 
selection media for 21 days post-transduction and the frequencies of integration 
(demonstrated by infectious titer) were determined by multiplying the number of viable 
colonies by their respective dilution factor.
Amplification of vector-genome junctions
Illegitimate integration was quantified by isolating drug-resistant clones after transducing 
HEK 293 cells with a Bleomycin resistance transgene. Transduced cells were selected for 
three weeks prior to isolation, after which genomic DNA was extracted using the Puregene 
DNA Purification Kit (Gentra Systems, Inc., Minneapolis, MN). The vector-genome 
junctions were then amplified by linear amplification mediated PCR (LAM-PCR) off of the 
3’ LTR as previously described46 in two separate experiments (CS-CZW n =12; IN/D116N 
n=7, 12; LTR/U3att n=8, 11; LTR/U3att-IN/D116N n=4, 9) and/or by a modified technique 
adapted from Ravin, et al47 and Zhou, et al48 (IN/D116N n=12; LTR/U3att n=18; LTR/
U3att-IN/D116N n=22). Briefly, to perform the modified technique for surveying insertion 
sites, the genomic DNA was first sheared to an approximate size of 1,000 bp using Covaris 
sonication (Covaris, Wohurn, MA). Starting with 1000 ng of sheared fragments, the ends 
were repaired using the NEBNext End Repair Module (NEB, Ipswich, MA) and 3’ dA-tailed 
with the NEBNext dA-Tailing Module (NEB, Ipswich, MA). Products greater than ~300 bp 
were selected and purified using a 0.8:1 ratio of AMPure XP beads (Beckman Coulter, Brea, 
CA) to dA-tailed product. A partially double stranded linker cassette with a 5’ T-overhang 
(LamTlinkerL: 5’ GACCCGGGAGATCTGAATTCAGTGGCACAGCAGTTAGGT 3’; 
LamTlinkerS: 5' CCTAACTGCTGTGCCACT 3’) was then ligated to the ends of the 
purified products using the Fast-Link DNA Ligation kit (Epicentre, Madison, WI). 
Exponential PCR was performed using the ligation product as a template with a biotinylated 
vector-specific primer for the 5’ or 3’ end of the vector and a linker-specific primer 
(LentiLAM-LC1: 5’ GACCCGGGAGATCTGAATTC 3’). Vector-specific PCR products 
were then enriched using Streptavidin-coated M-280 Dynabeads (Invitrogen, Carlsbad, CA). 
Next, nested PCR using a second indexed LTR-specific primer for the 5’ or 3’ end and 
another linker-specific primer (LentiLAM-LC2: 5’ AGTGGCACAGCAGTTAGG 3’) was 
performed using the enriched product as a template. The final PCR products were then 
purified using a 1.8:1 ratio of AMPure XP beads and quantified using a Qubit Fluorometer 
(Life Technologies, Grand Island, NY).
In order to confirm the insertion sites when LAM-PCR was performed solely off the 3’ LTR, 
conventional PCR was performed in order to amplify the 5’ vector-genome junction using 
the insertion site predicted by the 3’ LAM-PCR results.
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Vector insertion site analysis
Samples from the first LAM-PCR experimental group were analyzed by pyrosequencing 
(Roche 454 FLX Titanium) at the Indiana University Center for Genomics and 
Bioinformatics, Bloomington IN and analyzed using the SeqMap 2.0 web server platform49. 
Subsequent samples were analyzed using the Illumina MiSeq platform at the Genomics Core 
Facility of the University of Notre Dame. Paired-end reads of 250 base-pair were generated 
and in-house scripts were used to de-multiplex the reads and to retain paired-end reads that 
have both perfectly matched viral vector-specific primer and linker primer used in the last 
round of PCR. MiSeq adapter and linker sequences were trimmed off with Cutadapt version 
1.550. Paired-end reads were merged with PEAR version 0.9.5–6451. For the non-
overlapping paired-end reads, the reads containing the viral vector sequence were kept. The 
viral vector sequences in the merged reads were located with cross-match version .9909329 
(http://www.phrap.org). Reads with less than 30 base-pair viral vector sequence and less 
than 10 base-pair remaining genomic sequence were discarded. The remaining reads were 
further clustered with usearch7.0.1090_i86linux3252. Representative reads of each cluster 
were mapped to human reference genome hg19 using bwa version 0.7.5a53. Alignments 
demonstrating 100% sequence identity were designated as integration sites. The cross-match 
output, cluster and mapping information were compiled together in R54 and further 
analyzed.
Detection of vector DNA by PCR
Vector and 2-LTR circular DNA was detected using quantitative PCR assay based on a 
method previously described by Butler et al55. Total cellular DNA was prepared using a 
Puregene DNA Purification Kit (Gentra Systems, Inc., Minneapolis, MN), from which a 250 
ng or 500 ng sample was used for each reaction. To determine total, integrated, and 2-LTR 
circular vector DNA copy number, standard curves were generated by preparing serial 
dilutions of pcDNA-CS-CGW, genomic DNA from wild-type vector transduced HEK293 
cells, or a 2-LTR circle reference plasmid that was generated upon the introduction of a 2-
LTR fragment into a cloning vector, pCR4-TOPO (Invitrogen, Carlsbad, CA), respectively. 
Each sample was run in duplicate and data analysis was performed using Sequence 
Detection Systems 1.9.1 software (Applied Biosystems, Foster City, CA).
A 250 ng sample of total cellular DNA from transduced HEK293 cells at 3 days post-
transduction was used for detection of 1-LTR circular vector DNA by standard PCR. 1-LTR 
circles were amplified using the following primers: 5’-
GACCAATGACTTACAAGGCAGC-3’ (forward) and 5’-
GCAAGCCGAGTCCTGCGTCG-3’ (reverse). The cycling conditions were 95°C for 10 
min, thirty cycles of 92°C for 1 min, 56°C for 2 min, 72°C for 1.5 min, and 72°C for 7 min.
Detection of unintegrated vector DNA Southern blot analysis
Low molecular weight (Hirt) DNA (5–10 µg) purified from wild-type and mutant vector 
transduced HEK293, MO59J, and MO59K cells 3 days post-transduction, was digested 
overnight with BamHI and separated on an agarose gel. Briefly, the Hirt DNA extraction 
protocol was as follows. Transduced cells were resuspended in extraction buffer (0.6% SDS, 
0.01 M EDTA, and 0.01 M Tris) and 5M NaCl overnight at 4°C. The supernatant was 
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collected and the DNA was isolated by phenol-chloroform extraction. Upon transfer to a 
nylon membrane, the DNA was probed for GFP using a 32P-labeled eGFP probe prepared 
with a NEB Blot Kit (New England Biolabs, Ipswich, MA).
Detection of GFP mRNA by RT-PCR
Total cellular RNA was prepared from transduced HEK293 cells using a Qiagen RNeasy 
Micro Kit (Valencia, CA). For first strand cDNA synthesis, 200 ng of RNA was used in a 
reverse transcription reaction which included 0.5 µg of oligo(dT)12–18 primer and 2.5 units 
of HIV-1 reverse transcriptase (Ambion, Austin, TX). The reaction was incubated at 48°C 
for 30 minutes. About 5 µl of cDNA was used in a subsequent PCR reaction for 
amplification of GFP using the following primers: 5’-
TGACCCTGAAGTTCATCTGCACCA-3’ (forward) and 5’-
TGTGGCGGATCTTGAAGTTCACCT-3’ (reverse). The cycling conditions were 94°C for 5 
min, thirty cycles of 94°C for 30 sec, 60°C for 30 sec, 72°C for 30 sec, and 72°C for 7 min.
Statistical analysis
Quantitative data are represented as mean ± standard deviation of the mean. Data were 
analyzed using a two-tailed student’s t-test or analysis of variance (ANOVA). Differences 
were considered statistically significant for P-values less than 0.05.
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Figure 1. 
Integrase and LTR attachment site mutant vectors.(A) Integrase mutants derived upon 
mutation of the HIV-1 pol gene within the packaging plasmid, pMDL. Depicted are the 
locations of the c-terminal deletion and core domain point mutations. (B) LTR attachment 
site mutants derived upon deletion of the LTR attachment sites within the transfer vector, 
pcDNA-CS-CGW. Depicted are the locations of the 12 bp U3 (5’-ACTGGAAGGGCT-3’) 
and 11 bp U5 (5’-TCTCTAGCAGT-3’) attachment (att) site deletions. (C, D) Gag capsid 
protein (p24) was measured by ELISA in supernatants from 293T cells transfected with a 
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GFP (C) or bleomycin resistance transgene containing transfer plasmid (D). Data is 
represented as mean ± SD.
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Figure 2. 
Transduction of HEK293 cells.The percentage of GFP expressing cells (%GFP+ cells) 
determined by flow cytometry 3 days after transduction with (A) three integrase mutant 
vectors, IN/Δ174–288, IN/D116N, and IN/E152V, and (B) two LTR attachment site mutant 
vectors, LTR/U3del and LTR/U5del. For all transductions, mock transduced cells served as a 
negative control and integration-competent vector (IN+/LTR+) transduced cells served as a 
positive control. (C) Vector DNA copy number 4 hours after transduction, as determined by 
quantitative PCR. Data is represented as mean ± SD.
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Figure 3. 
Luciferase expression from transduced HEK293 cells.Firefly luciferase activity (relative 
light units, RLU) was measured 3 days after transduction. Luciferase activity from cells 
transduced with IN and LTR att site mutant vectors is shown relative to that achieved from 
integration-competent vector (IN+/LTR+). Data is represented as mean ± SD.
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Figure 4. 
GFP expression from transduced HEK293 cells.(A) The percentage of GFP expressing (% 
GFP+) cells 3–21 days after transduction. GFP expression was determined at 3, 9, 15, and 
21 days by flow cytometry. Data is represented as mean ± SD. (B) Total vector DNA copies 
estimated per GFP-expressing (GFP+) cell. Total vector DNA copy number was determined 
by quantitative PCR 3, 9, 15, and 21 days after transduction. Data is represented as mean ± 
SD. (C) GFP mRNA expression from vector DNA 21 days after transduction, as determined 
by RT-PCR.
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Figure 5. 
Frequency of integration in transduced HEK293 cells. Average antibiotic resistant colony 
formation titer assay results from two independent experiments comparing the frequency of 
integration among an integration competent vector (wt), a U3 LTR integrase attachment site 
mutant NILV (LTR/U3att), an integrase deficient NILV (IN/D116N), and a double mutant 
NILV (LTR/U3att-IN/D116N). Y-axis represents infectious units/ml of vector supernatant. 
Error bars indicate standard deviation of the mean. * - p < 0.05; ** - p < 0.005
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Figure 6. 
Vector-genome junctions of transduced HEK293 clones. Summary of results obtained from 
sequencing of Zeocin selected clones transduced with a normal integrating vector (CS-
CZW), an integrase catalytic core mutant NILV (IN/D116N), a U3 LTR integrase attachment 
sited deleted NILV (LTR/U3att) and a double mutant (LTR/U3att-IN/D116N).Red 
highlighted base-pairs indicate flanking 5-bp repeat of genomic DNA by integrase-mediated 
strand-transfer; underlined TG/CA dinucleotides represent end-processing by a functional 
integrase protein; inverted black triangles represent LTR truncations; red highlighted triangle 
represents deletions of genomic DNA; black squares indicate insertions at the vector-
genome junction.
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Figure 7. 
Unintegrated linear and circular vector DNA in transduced HEK293 cells.(A) Southern blot 
analysis of unintegrated vector DNA from low molecular weight (Hirt) DNA prepared from 
transduced cells 3 days after transduction. Linear (2667 bp), 1-LTR circular (c1-LTR, 4185 
bp), and 2-LTR circular (c2-LTR, 4688 bp) vector DNA forms are detected upon 
hybridization of a radiolabeled eGFP probe. (B) 2-LTR circles estimated per GFP-
expressing (GFP+) cell. 2-LTR circular vector DNA copy number was determined by 
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quantitative PCR 3, 9, 15, and 21 days after transduction. Data is represented as mean ± SD. 
(C) Amplification of 1-LTR circles 3, 9, 15, and 21 days after transduction by standard PCR.
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Figure 8. 
Vector DNA in transduced MO59K (DNA-PKcs+) and MO59J (DNA-PKcs−) cells. (A) 
Southern blot analysis of unintegrated vector DNA from low molecular weight DNA 
prepared from transduced cells 3 days after transduction. Vector DNA forms are detected 
upon hybridization of a radiolabeled eGFP probe. (B) 2-LTR circles estimated per GFP-
expressing (GFP+) cell by quantitative PCR 3 days after transduction.
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Figure 9. 
The frequency of integration in NILV with combined modifications for inhibiting 
integration.Average bleomycin resistant colony formation assay results from two 
experiments comparing the frequency of integration among combined mutations to LV 
design. The horizontal axis designates the independent modification or combining it with the 
indicated mutation(s). CS-CZW - an integration competent vector; ΔPPT - an NILV with a 
deletion of the 3’ polypurine tract; IN/D116N - an integrase deficient NILV; LTR/U3att - a 
U3 LTR integrase attachment site mutant NILV. Data is represented as mean ± SD.
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Figure 10. 
The effect of combining modifications to reduce integration frequency on transgene 
expression.Average flow cytometry results for GFP expression from two experiments 
comparing the levels among combined modifications to lentiviral vector design. Bars 
indicate the geometric mean fluorescence intensity (MFI) for the indicated vector on the x-
axis. CS-CGW - normal integrating vector (wild-type); ΔPPT - NILV with a deletion of the 
3’ polypurine tract; IN/D116N - an integrase deficient NILV; LTR/U3att - a U3 LTR 
integrase attachment site mutant NILV. Data is represented as mean ± SD.
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